Millipore Sigma Vibrant Logo

PF024 MMP-9, Active, Human, Recombinant

MMP-9, Active, Human, Recombinant : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: Gelatinase B, Matrix Metalloproteinase 9, 83 kDa Gelatinase

View Products on Sigmaaldrich.com
PF024
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
PF024-5UG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 μg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewRecombinant, human MMP-9 purified from transfected mammalian cells and activated with APMA. Active MMP-9 enzyme is APMA-free.
      Catalogue NumberPF024
      Brand Family Calbiochem®
      SynonymsGelatinase B, Matrix Metalloproteinase 9, 83 kDa Gelatinase
      References
      ReferencesParsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
      Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
      Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
      Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
      Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
      Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
      Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
      Liotta, L.A., et al. 1991. Cell 64, 327.
      Harris, E. 1990. N. Engl. J. Med. 322, 1277.
      Product Information
      ActivityΔA₄₀₅/hour/µg protein ≥8.0 in standard thiopeptolide hydrolysis assays.
      EC number3.4.24.35
      FormLiquid
      FormulationIn 50 mM HEPES, 10 mM CaCl₂, 20% glycerol, 0.005% BRIJ®-35 Detergent, pH 7.5.
      PreservativeNone
      Quality LevelMQ200
      Applications
      Application ReferencesZymography Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259. Kleiner, D.E. and Stetler-Stevenson W.G. 1994. Anal. Biochem. 218, 325. Heussen, C. and Dowdle, E.B. 1980. Anal. Biochem. 102, 196. Substrate cleavage assay Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
      Biological Information
      Purity≥90% by SDS-PAGE
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot into siliconized vials and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      PF024-5UG 07790788056438

      Documentation

      MMP-9, Active, Human, Recombinant FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      MMP-9, Active, Human, Recombinant Certificats d'analyse

      TitreNuméro de lot
      PF024

      Références bibliographiques

      Aperçu de la référence bibliographique
      Parsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
      Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
      Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
      Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
      Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
      Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
      Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
      Liotta, L.A., et al. 1991. Cell 64, 327.
      Harris, E. 1990. N. Engl. J. Med. 322, 1277.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision06-July-2010 JSW
      SynonymsGelatinase B, Matrix Metalloproteinase 9, 83 kDa Gelatinase
      DescriptionRecombinant, human MMP-9 purified from transfected mammalian cells and activated with APMA. Active MMP-9 enzyme is APMA-free. Supplied as the ~83 kDa active enzyme. The proenzyme form of MMP-9 was purified from transfected mammalian cells and activated using the organomercurial compound, 4-aminophenyl mercuric acetate (APMA). APMA is removed through a desalting column. The substrate specificity for MMP-9 is collagen (types IV, V, VII, and X), elastin, and gelatin (type I). Useful for immunoblotting, substrate cleavage, and zymography. Titration is recommended for optimal results in individual systems. Matrix metalloproteinases are members of a unique family of proteolytic enzymes that have a zinc ion at their active sites and can degrade collagens, elastin and other components of the extracellular matrix (ECM). These enzymes are present in normal healthy individuals and have been shown to have an important role in processes such as wound healing, pregnancy, and bone resorption. However, overexpression and activation of MMPs have been linked with a range of pathological processes and disease states involved in the breakdown and remodeling of the ECM. Such diseases include tumor invasion and metastasis, rheumatoid arthritis, periodontal disease, and vascular processes such as angiogenesis, intimal hyperplasia, atherosclerosis, and aneurysms. Recently, MMPs have been linked to neurodegenerative diseases such as Alzheimer's, and amyotrophic lateral sclerosis (ALS). Natural inhibitors of MMPs, tissue inhibitor of matrix metalloproteinases (TIMPs) exist and synthetic inhibitors have been developed which offer hope of new treatment options for these diseases.

      Regulation of MMP activity can occur at the level of gene expression, including transcription and translation, level of activation, or at the level of inhibition by TIMPs. Thus, perturbations at any of these points can theoretically lead to alterations in ECM turnover. Expression is under tight control by pro- and anti-inflammatory cytokines and/or growth factors and, once produced the enzymes are usually secreted as inactive zymograms. Upon activation (removal of the inhibitory propeptide region of the molecules) MMPs are subject to control by locally produced TIMPs. All MMPs can be activated in vitro with organomercurial compounds (e.g. 4-aminophenylmercuric acetate), but the agents responsible for the physiological activation of all MMPs have not been clearly defined. Numerous studies indicate that members of the MMP family have the ability to activate one another. The activation of the MMPs in vivo is likely to be a critical step in terms of their biological behavior, because it is this activation that will tip the balance in favor of ECM degradation. The hallmark of diseases involving MMPs appear to be stoichiometric imbalance between active MMPs and TIMPs, leading to excessive tissue disruption and often degradation. Determination of the mechanisms that control this imbalance may open up some important therapeutic options of specific enzyme inhibitors.
      FormLiquid
      FormulationIn 50 mM HEPES, 10 mM CaCl₂, 20% glycerol, 0.005% BRIJ®-35 Detergent, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      EC number3.4.24.35
      Purity≥90% by SDS-PAGE
      ActivityΔA₄₀₅/hour/µg protein ≥8.0 in standard thiopeptolide hydrolysis assays.
      PreservativeNone
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot into siliconized vials and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesParsons, S.L., et al. 1997. Br. J. Surg. 84, 160.
      Backstrom, J.R., et al. 1996. J. Neuro. 16, 7910.
      Lim, G.P., et al. 1996. J. Neurochem. 67, 251.
      Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.
      Sang, Q.X., et al. 1995. Biochim. Biophys. Acta 1251, 99.
      Zempo, N., et al. 1994. J. Vasc. Surg. 20, 217.
      Birkedal-Hansen, H. 1993. J. Periodontol. 64, 484.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Jeffrey, J.J. 1991. Semin. Perinatol. 15, 118.
      Liotta, L.A., et al. 1991. Cell 64, 327.
      Harris, E. 1990. N. Engl. J. Med. 322, 1277.
      Application referencesZymography Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259. Kleiner, D.E. and Stetler-Stevenson W.G. 1994. Anal. Biochem. 218, 325. Heussen, C. and Dowdle, E.B. 1980. Anal. Biochem. 102, 196. Substrate cleavage assay Xia, T., et al. 1996. Biochim. Biophys. Acta 1293, 259.